Mark Lennihan | Associated Press file photo
Other companies are following Pfizer’s lead. Switzerland’s Novartis AG is offering coupons to patients with commercial insurance valid through December 2013 for $4-a-month copays on its Diovan and Diovan HCT, with the company covering the next $50 in out-of-pocket costs.
Court documents show trail of deception on Celebrex
Research» Pfizer defends decision to release partial results about drug’s safety.
By KATIE THOMAS
| The New York Times
First Published Jul 07 2012 07:47 pm • Last Updated Oct 30 2012 11:31 pm
This article cannot be shown due to contract restrictions.
Brigham Young University and professor Daniel Simmons sued Pfizer in 2006, saying Simmons had made a critical discovery that led to the development of Celebrex but that he and BYU had been denied a share of profits. Pfizer agreed to settle the case earlier this year for $450 million. That lawsuit was not associated with a pending securities fraud case against Pfizer.
Reader comments on sltrib.com are the opinions of the writer, not The Salt Lake Tribune. We will delete comments containing obscenities, personal attacks and inappropriate or offensive remarks. Flagrant or repeat violators will be banned. If you see an objectionable comment, please alert us by clicking the arrow on the upper right side of the comment and selecting "Flag comment as inappropriate". If you've recently registered with Disqus or aren't seeing your comments immediately, you may need to verify your email address. To do so, visit disqus.com/account. See more about comments here.